Astria Therapeutics' STAR-0215 offers revolutionary HAE treatment with superior results and minimal risks. Click here to find ...

KalVista's sebetralstat shows strong phase 3 results for HAE, but financial concerns and competition make investing cautious. Click here to read more.

CRISPR gene editing based treatment reduced HAE attacks rates by up to 80%. NTLA-2002 was well tolerated by patients. The ...

Research Triangle Park, North Carolina Tuesday, November 19, 2024, 16:00 Hrs [IST] ...

About ORLADEYO ® (berotralstat) ORLADEYO® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 ...

About Sebetralstat Discovered and developed entirely by the scientific team at KalVista, sebetralstat is a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of HAE.

About Sebetralstat Discovered and developed entirely by the scientific team at KalVista, sebetralstat is a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of HAE.

They found that both dosages led to a reduction in angioedema attacks as well as a sustained and meaningful reduction in kallikrein levels in HAE patients. "This reduction is perhaps the most ...

This group has previously demonstrated that endothelial expression of kallikrein related-peptidase 10 (KLK10) is elevated arteries in conditions of high stable flow and down-regulated by disturbed ...